Pemphigus vulgaris lesion. Pemphigus vulgaris
Conditions
Interventions
Intervention 1: Intervention group: First intervention: Systemic administration intervention where a 50 cc vial of rituximab containing 500 mg/50 ml is injected intravenously to patients four times wi
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: People over 18 years old with pemphigus vulgaris with oral lesions Patients who have not had a therapeutic response to corticosteroid administration Patients for whom rituximab has been started
Exclusion criteria
Exclusion criteria: Pregnancy and breastfeeding People who have coagulation problems Patients with infection at the site of the lesion Rituximab contraindications include hypersensitivity to it or its components Having hepatitis B Having cardiovascular diseases Having malignant diseases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of pemphigus vulgaris lesion. Timepoint: Before the study, on the 15th day, 33 months after the injection. Method of measurement: PVLSS: Pemphigus Vulgaris Lesion Severity Score.;Patient satisfaction. Timepoint: Before the study, on the 15th day, 33 months after the injection. Method of measurement: VAS: Visual analogue Scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Faegheh Sheikhalizadeh Nobar
Tabriz University of Medical Sciences
Outcome results
None listed